181 related articles for article (PubMed ID: 37521871)
1. Isotoosendanin exerts inhibition on triple-negative breast cancer through abrogating TGF-
Zhang J; Zhang Z; Huang Z; Li M; Yang F; Wu Z; Guo Q; Mei X; Lu B; Wang C; Wang Z; Ji L
Acta Pharm Sin B; 2023 Jul; 13(7):2990-3007. PubMed ID: 37521871
[TBL] [Abstract][Full Text] [Related]
2. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.
Yi M; Wu Y; Niu M; Zhu S; Zhang J; Yan Y; Zhou P; Dai Z; Wu K
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460337
[TBL] [Abstract][Full Text] [Related]
3. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
4. Brazilein inhibits epithelial-mesenchymal transition (EMT) and programmed death ligand 1 (PD-L1) expression in breast cancer cells.
Wudtiwai B; Kodchakorn K; Shwe TH; Pothacharoen P; Phitak T; Suninthaboonrana R; Kongtawelert P
Int Immunopharmacol; 2023 May; 118():109988. PubMed ID: 36933493
[TBL] [Abstract][Full Text] [Related]
5. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
6. RNA
Tan B; Zhou K; Liu W; Prince E; Qing Y; Li Y; Han L; Qin X; Su R; Pokharel SP; Yang L; Zhao Z; Shen C; Li W; Chen Z; Zhang Z; Deng X; Small A; Wang K; Leung K; Chen CW; Shen B; Chen J
Theranostics; 2022; 12(13):5727-5743. PubMed ID: 35966596
[TBL] [Abstract][Full Text] [Related]
7. Quaking 5 suppresses TGF-β-induced EMT and cell invasion in lung adenocarcinoma.
Wang S; Tong X; Li C; Jin E; Su Z; Sun Z; Zhang W; Lei Z; Zhang HT
EMBO Rep; 2021 Jun; 22(6):e52079. PubMed ID: 33769671
[TBL] [Abstract][Full Text] [Related]
8. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer.
Saleh R; Taha RZ; Sasidharan Nair V; Alajez NM; Elkord E
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31349612
[TBL] [Abstract][Full Text] [Related]
11. Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation.
Pai JT; Chen XH; Leu YL; Weng MS
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163593
[TBL] [Abstract][Full Text] [Related]
12. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
13. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA‑133b targets TGFβ receptor I to inhibit TGF‑β‑induced epithelial‑to‑mesenchymal transition and metastasis by suppressing the TGF‑β/SMAD pathway in breast cancer.
Wang S; Huang M; Wang Z; Wang W; Zhang Z; Qu S; Liu C
Int J Oncol; 2019 Nov; 55(5):1097-1109. PubMed ID: 31545407
[TBL] [Abstract][Full Text] [Related]
16. USP1-WDR48 deubiquitinase complex enhances TGF-β induced epithelial-mesenchymal transition of TNBC cells via stabilizing TAK1.
Han D; Wang L; Chen B; Zhao W; Liang Y; Li Y; Zhang H; Liu Y; Wang X; Chen T; Li C; Song X; Luo D; Li Z; Yang Q
Cell Cycle; 2021 Feb; 20(3):320-331. PubMed ID: 33461373
[TBL] [Abstract][Full Text] [Related]
17. Endothelial cells promote triple-negative breast cancer cell metastasis
Zhang W; Xu J; Fang H; Tang L; Chen W; Sun Q; Zhang Q; Yang F; Sun Z; Cao L; Wang Y; Guan X
FASEB J; 2018 Jan; 32(1):276-288. PubMed ID: 28899878
[TBL] [Abstract][Full Text] [Related]
18. miR-425 suppresses EMT and the development of TNBC (triple-negative breast cancer) by targeting the TGF-β 1/SMAD 3 signaling pathway.
Liu Y; Chen J
RSC Adv; 2018 Dec; 9(1):151-165. PubMed ID: 35521597
[No Abstract] [Full Text] [Related]
19. Enterolactone modulates the ERK/NF-κB/Snail signaling pathway in triple-negative breast cancer cell line MDA-MB-231 to revert the TGF-β-induced epithelial-mesenchymal transition.
Mali AV; Joshi AA; Hegde MV; Kadam SS
Cancer Biol Med; 2018 May; 15(2):137-156. PubMed ID: 29951338
[TBL] [Abstract][Full Text] [Related]
20. Berberine Suppresses Cell Motility Through Downregulation of TGF-β1 in Triple Negative Breast Cancer Cells.
Kim S; Lee J; You D; Jeong Y; Jeon M; Yu J; Kim SW; Nam SJ; Lee JE
Cell Physiol Biochem; 2018; 45(2):795-807. PubMed ID: 29414799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
